JP2016526011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526011A5 JP2016526011A5 JP2016507628A JP2016507628A JP2016526011A5 JP 2016526011 A5 JP2016526011 A5 JP 2016526011A5 JP 2016507628 A JP2016507628 A JP 2016507628A JP 2016507628 A JP2016507628 A JP 2016507628A JP 2016526011 A5 JP2016526011 A5 JP 2016526011A5
- Authority
- JP
- Japan
- Prior art keywords
- core
- nanoparticle
- polymer
- inflammatory agent
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 claims description 44
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 28
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 28
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229940127089 cytotoxic agent Drugs 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 16
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical group NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 2
- 229940046231 pamidronate Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000000034 method Methods 0.000 description 7
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361810076P | 2013-04-09 | 2013-04-09 | |
| US61/810,076 | 2013-04-09 | ||
| PCT/US2014/033431 WO2014169007A2 (en) | 2013-04-09 | 2014-04-09 | Combination therapeutic nanoparticles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075876A Division JP2017119721A (ja) | 2013-04-09 | 2017-04-06 | 併用療法用ナノ粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526011A JP2016526011A (ja) | 2016-09-01 |
| JP2016526011A5 true JP2016526011A5 (https=) | 2017-05-25 |
Family
ID=51690117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507628A Pending JP2016526011A (ja) | 2013-04-09 | 2014-04-09 | 併用療法用ナノ粒子 |
| JP2017075876A Pending JP2017119721A (ja) | 2013-04-09 | 2017-04-06 | 併用療法用ナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075876A Pending JP2017119721A (ja) | 2013-04-09 | 2017-04-06 | 併用療法用ナノ粒子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170000740A9 (https=) |
| EP (1) | EP2983648A4 (https=) |
| JP (2) | JP2016526011A (https=) |
| WO (1) | WO2014169007A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033513A1 (en) | 2011-08-31 | 2013-03-07 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
| US20170190726A9 (en) * | 2013-12-12 | 2017-07-06 | University Of Georgia Research Foundation, Inc. | Prodrug for release of cisplatin and cyclooxygenase inhibitor |
| WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
| JP2017530941A (ja) * | 2014-08-04 | 2017-10-19 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 脳内に蓄積する治療用ナノ粒子 |
| SG11201802073YA (en) | 2015-09-15 | 2018-04-27 | Samyang Biopharmaceuticals | Pharmaceutical composition containing anionic drug, and preparation method therefor |
| WO2017048018A1 (ko) * | 2015-09-15 | 2017-03-23 | 주식회사 삼양바이오팜 | 음이온성 약물 함유 약제학적 조성물 및 그 제조방법 |
| CN107296794A (zh) * | 2017-07-27 | 2017-10-27 | 中国药科大学 | 两亲性非甾体抗炎合铂纳米粒及其制备方法 |
| KR101991328B1 (ko) * | 2018-02-02 | 2019-06-21 | 서울대학교산학협력단 | 마이크로버블-멜라닌 나노입자-펩타이드 복합체 및 이의 제조방법 |
| CN115120733B (zh) * | 2021-03-24 | 2025-03-14 | 中国医学科学院药物研究所 | 一种核酸和化药共递送聚合物组合物、其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367113B2 (en) * | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| WO2008124632A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| BRPI0810899A2 (pt) * | 2007-04-13 | 2014-10-29 | Univ North Texas | Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais. |
| WO2009070302A1 (en) * | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| CN102791294A (zh) * | 2009-12-16 | 2012-11-21 | 布里格姆妇女医院股份有限公司 | 用于多种药物递送的粒子 |
| WO2014059022A1 (en) * | 2012-10-09 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use |
-
2014
- 2014-04-09 WO PCT/US2014/033431 patent/WO2014169007A2/en not_active Ceased
- 2014-04-09 JP JP2016507628A patent/JP2016526011A/ja active Pending
- 2014-04-09 US US14/782,618 patent/US20170000740A9/en not_active Abandoned
- 2014-04-09 EP EP14782682.0A patent/EP2983648A4/en not_active Withdrawn
-
2017
- 2017-04-06 JP JP2017075876A patent/JP2017119721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526011A5 (https=) | ||
| Eloy et al. | Immunoliposomes: A review on functionalization strategies and targets for drug delivery | |
| Shefet-Carasso et al. | Antibody-targeted drugs and drug resistance—challenges and solutions | |
| Kanwar et al. | Neurological disorders and therapeutics targeted to surmount the blood–brain barrier | |
| JP2016522261A5 (https=) | ||
| Chu et al. | Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis | |
| ES2606173T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención del cáncer | |
| JP2016511747A5 (https=) | ||
| JP2016535009A5 (https=) | ||
| JP2013518912A5 (https=) | ||
| JP2018502120A5 (https=) | ||
| JP2008502584A5 (https=) | ||
| JP2015509097A5 (https=) | ||
| JP2019531293A5 (https=) | ||
| CY1120419T1 (el) | Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμου | |
| JP2013100314A5 (https=) | ||
| JP2017521486A5 (https=) | ||
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| JP2010514839A5 (https=) | ||
| JP2017534254A5 (https=) | ||
| JP2017500285A5 (https=) | ||
| JP2016509011A5 (https=) | ||
| RU2016144055A (ru) | Конъюгаты лекарственного средства с наночастицами | |
| EP4434540A3 (en) | Humanized anti-il-1r3 antibodies | |
| CN110337444A (zh) | 穿越血脑屏障的纳米药物载体 |